Markers of plaque instability in the early diagnosis and risk stratification of acute myocardial infarction

Clinical Chemistry

Volumn 58, Issue 1, 2012, Pages 246-256

  Schaub, Nora ^a   Reichlin, Tobias ^a,b   Meune, Christophe ^a   Twerenbold, Raphael ^a   Haaf, Philip ^a   Hochholzer, Willibald ^a   Niederhauser, Nadine ^a   Bosshard, Piet ^a   Stelzig, Claudia ^a   Freese, Michael ^a   Reiter, Miriam ^a   Gea, Joachim ^c   Buser, Andreas ^a   Mebazaa, Alexandre ^a,d   Osswald, Stefan ^a   Mueller, Christian ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HOSPITAL DEL MAR   (Spain)

^d HÔPITAL LARIBOISIÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; MYELOPEROXIDASE; PREGNANCY ASSOCIATED PLASMA PROTEIN A; TROPONIN T;

ACUTE HEART INFARCTION; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CARDIOLOGIST; CONTROLLED STUDY; DEATH; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; EARLY DIAGNOSIS; EMERGENCY WARD; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PROTEIN ANALYSIS; RISK; SENSITIVITY ANALYSIS; STRATIFICATION; SURVIVOR; THORAX PAIN;

ACUTE CORONARY SYNDROME; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CALGRANULIN A; CALGRANULIN B; CHEST PAIN; EARLY DIAGNOSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEROXIDASE; PLAQUE, ATHEROSCLEROTIC; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PROGNOSIS; RISK ASSESSMENT; ROC CURVE; TROPONIN T;

EID: 84856074886     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2011.172940     Document Type: Article

References (40)

1. Nawar EW, Niska RW, Xu J. National Hospital Ambulatory Medical Care Survey: 2005 Emergency Department Summary. Adv Data 2007;386:1-32.
2. Boersma E, Pieper KS, Steyerberg EW, Wilcox RG, Chang WC, Lee KL, et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation: results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation 2000;101:2557-67. (Pubitemid 30350632)
3. Heidenreich PA, Alloggiamento T, Melsop K, McDonald KM, Go AS, Hlatky MA. The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: a meta-analysis. J Am Coll Cardiol 2001;38:478-85. (Pubitemid 32721777)
4. Apple FS, Pearce LA, Chung A, Ler R, Murakami MM. Multiple biomarker use for detection of adverse events in patients presenting with symptoms suggestive of acute coronary syndrome. Clin Chem 2007;53:874-81. (Pubitemid 46744243)
5. Mueller C, Neumann FJ, Perruchoud AP, Zeller T, Buettner HJ. Prognostic value of quantitative troponin T measurements in unstable angina/non-ST-segment elevation acute myocardial infarction treated early and predominantly with percutaneous coronary intervention. Am J Med 2004;117:897-902. (Pubitemid 40075556)
6. Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M, et al. Universal definition of myocardial infarction. Circulation 2007;116:2634-53. (Pubitemid 350182388)
7. Nicholls SJ, Hazen SL. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol 2005;25:1102-11. (Pubitemid 40776595)
8. Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003;349:1595-604. (Pubitemid 37288567)
9. Stefanescu A, Braun S, Ndrepepa G, Koppara T, Pavaci H, Mehilli J, et al. Prognostic value of plasma myeloperoxidase concentration in patients with stable coronary artery disease. Am Heart J 2008;155:356-60.
10. Baldus S, Rudolph V, Roiss M, Ito WD, Rudolph TK, Eiserich JP, et al. Heparins increase endothelial nitric oxide bioavailability by liberating vessel-immobilized myeloperoxidase. Circulation 2006;113:1871-8. (Pubitemid 43739399)
11. Rudolph TK, Rudolph V, Witte A, Klinke A, Szoecs K, Lau D, et al. Liberation of vessel adherent myeloperoxidase by enoxaparin improves endothelial function. Int J Cardiol 2010;140:42-7.
12. Ionita MG, Vink A, Dijke IE, Laman JD, Peeters W, van der Kraak PH, et al. High levels of myeloidrelated protein 14 in human atherosclerotic plaques correlate with the characteristics of rupture-prone lesions. Arterioscler Thromb Vasc Biol 2009;29:1220-7.
13. Altwegg LA, Neidhart M, Hersberger M, Muller S, Eberli FR, Corti R, et al. Myeloid-related protein 8/14 complex is released by monocytes and granulocytes at the site of coronary occlusion: a novel, early, and sensitive marker of acute coronary syndromes. Eur Heart J 2007;28:941-8. (Pubitemid 47343918)
14. Morrow DA, Wang Y, Croce K, Sakuma M, Sabatine MS, Gao H, et al. Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial. Am Heart J 2008;155:49-55. (Pubitemid 350234770)
15. Bayes-Genis A, Conover CA, Overgaard MT, Bailey KR, Christiansen M, Holmes DR Jr, et al. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med 2001;345:1022-9.
16. Iversen KK, Dalsgaard M, Teisner AS, Schoos M, Teisner B, Nielsen H, et al. Pregnancy-associated plasma protein-A, a marker for outcome in patients suspected for acute coronary syndrome. Clin Biochem 2010;43:851-7.
17. Iversen KK, Teisner B, Winkel P, Gluud C, Kjoller E, Kolmos HJ, et al. Pregnancy associated plasma protein-A as a marker for myocardial infarction and death in patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial. Atherosclerosis 2011;214:203-8.
18. Iversen KK, Dalsgaard M, Teisner AS, Schoos M, Teisner B, Nielsen H, et al. Usefulness of pregnancy-associated plasma protein A in patients with acute coronary syndrome. Am J Cardiol 2009;104:1465-71.
19. Lund J, Wittfooth S, Qin QP, Ilva T, Porela P, Pulkki K, et al. Free vs total pregnancy-associated plasma protein A (PAPP-A) as a predictor of 1-year outcome in patients presenting with non-ST-elevation acute coronary syndrome. Clin Chem 2010;56:1158-65.
20. Anzai T, Yoshikawa T, Shiraki H, Asakura Y, Akaishi M, Mitamura H, Ogawa S. C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. Circulation 1997;96:778-84. (Pubitemid 27329609)
21. Mueller C, Buettner HJ, Hodgson JM, Marsch S, Perruchoud AP, Roskamm H, Neumann FJ. Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients. Circulation 2002;105:1412-5. (Pubitemid 34263269)
22. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363-9. (Pubitemid 36158034)
23. Suleiman M, Khatib R, Agmon Y, Mahamid R, Boulos M, Kapeliovich M, et al. Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein. J Am Coll Cardiol 2006;47:962-8.
24. Reichlin T, Hochholzer W, Bassetti S, Steuer S, Stelzig C, Hartwiger S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 2009;361:858-67.
25. Reichlin T, Hochholzer W, Stelzig C, Laule K, Freidank H, Morgenthaler NG, et al. Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol 2009;54:60-8.
26. Reichlin T, Irfan A, Twerenbold R, Reiter M, Hochholzer W, Burkhalter H, et al. Utility of absolute and relative changes in cardiac troponin concentrations in the early diagnosis of acute myocardial infarction. Circulation 2011;124:136-45.
27. Thygesen K, Mair J, Katus H, Plebani M, Venge P, Collinson P, et al. Recommendations for the use of cardiac troponin measurement in acute cardiac care. Eur Heart J 2010;31:2197-204.
28. Apple FS, Wu AH, Jaffe AS. European Society of Cardiology and American College of Cardiology guidelines for redefinition of myocardial infarction: how to use existing assays clinically and for clinical trials. Am Heart J 2002;144:981-6. (Pubitemid 36026910)
29. Apple FS, Jesse RL, Newby LK, Wu AH, Christenson RH. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical issues for biochemical markers of acute coronary syndromes. Circulation 2007;115:e352-5. (Pubitemid 46648623)
30. Giannitsis E, Kurz K, Hallermayer K, Jarausch J, Jaffe AS, Katus HA. Analytical validation of a high-sensitivity cardiac troponin T assay. Clin Chem 2010;56:254-61.
31. Healy AM, Pickard MD, Pradhan AD, Wang Y, Chen Z, Croce K, et al. Platelet expression profiling and clinical validation of myeloid-related protein-14 as a novel determinant of cardiovascular events. Circulation 2006;113:2278-84. (Pubitemid 43947973)
32. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247-54. (Pubitemid 46768608)
33. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-45.
34. Romanens M, Ackermann F, Spence JD, Darioli R, Rodondi N, Corti R, et al. Improvement of cardiovascular risk prediction: time to review current knowledge, debates, and fundamentals on how to assess test characteristics. Eur J Cardiovasc Prev Rehabil 2010;17:18-23.
35. Iversen K, Teisner A, Dalager S, Olsen KE, Floridon C, Teisner B. Pregnancy associated plasma protein-A (PAPP-A) is not a marker of the vulnerable atherosclerotic plaque. Clin Biochem 2011;44:312-8.
36. Ndrepepa G, Braun S, Mehilli J, von Beckerath N, Schomig A, Kastrati A. Myeloperoxidase level in patients with stable coronary artery disease and acute coronary syndromes. Eur J Clin Invest 2008;38:90-6. (Pubitemid 351143413)
37. Zhang R, Brennan ML, Fu X, Aviles RJ, Pearce GL, Penn MS, et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001;286:2136-42. (Pubitemid 34041599)
38. Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Munzel T, et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003;108:1440-5. (Pubitemid 37176448)
39. Dominguez-Rodriguez A, Samimi-Fard S, Abreu-Gonzalez P, Garcia-Gonzalez MJ, Kaski JC. Prognostic value of admission myeloperoxidase levels in patients with ST-segment elevation myocardial infarction and cardiogenic shock. Am J Cardiol 2008;101:1537-40.
40. Mocatta TJ, Pilbrow AP, Cameron VA, Senthilmohan R, Frampton CM, Richards AM, Winterbourn CC. Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. J Am Coll Cardiol 2007;49:1993-2000. (Pubitemid 46734639)